Unicycive Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Unicycive received a June 2026 Complete Response Letter (CRL) for its oxylanthanum carbonate (OLC) NDA citing third-party manufacturing deficiencies (same issues as June 2025 CRL); FDA has assigned a facility inspection to the vendor, with no clinical efficacy or safety concerns raised. As of June 30, 2026, the company holds $61.4M in cash/equivalents/marketable securities and expects runway into 2027; Q2 2026 net loss was $1.7M ($0.06/share) versus $6.5M loss in Q2 2025, driven partly by $8.0M favorable warrant liability adjustment.
Why this rating
OLC resubmission path is real and near-term (post-inspection), but manufacturing deficiency recurrence raises approval uncertainty. Cash position ($61.4M) is ~95% of $64.3M market cap—adequate but not expansive. Material near-term event but execution risk remains.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.